Labcorp Holdings Inc. (NYSE:LH) Receives $308.00 Consensus Target Price from Analysts

Labcorp Holdings Inc. (NYSE:LH) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $308.00.

LH has been the topic of several analyst reports. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Robert W. Baird set a $334.00 target price on Labcorp in a research note on Friday, May 1st. Evercore reissued an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th.

Insider Transactions at Labcorp

In other news, EVP Kathryn W. Kyle sold 762 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $263.89, for a total transaction of $201,084.18. Following the sale, the executive vice president owned 3,813 shares of the company’s stock, valued at $1,006,212.57. This trade represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the sale, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. This represents a 5.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.84% of the company’s stock.

Institutional Investors Weigh In On Labcorp

A number of hedge funds have recently modified their holdings of LH. UBS Group AG raised its position in Labcorp by 2.2% in the 4th quarter. UBS Group AG now owns 495,535 shares of the medical research company’s stock valued at $124,320,000 after buying an additional 10,706 shares during the last quarter. Dakota Wealth Management raised its position in Labcorp by 98.6% in the 3rd quarter. Dakota Wealth Management now owns 10,303 shares of the medical research company’s stock valued at $2,958,000 after buying an additional 5,116 shares during the last quarter. Cinctive Capital Management LP acquired a new stake in Labcorp in the 3rd quarter valued at approximately $3,297,000. 8 Knots Management LLC raised its position in Labcorp by 96.6% in the 3rd quarter. 8 Knots Management LLC now owns 204,859 shares of the medical research company’s stock valued at $58,807,000 after buying an additional 100,675 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its position in Labcorp by 50.8% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,419 shares of the medical research company’s stock valued at $7,871,000 after buying an additional 9,231 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Trading Up 3.0%

NYSE:LH opened at $279.60 on Tuesday. Labcorp has a 1-year low of $241.81 and a 1-year high of $293.72. The business’s 50-day moving average price is $261.22 and its two-hundred day moving average price is $265.68. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $22.93 billion, a price-to-earnings ratio of 24.77, a PEG ratio of 1.90 and a beta of 0.90.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the prior year, the firm posted $3.84 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities analysts expect that Labcorp will post 18 earnings per share for the current year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Friday, May 29th were given a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.